These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 9704427)
1. Thrombopoietins and thrombopoiesis: a clinical perspective. Kuter DJ Vox Sang; 1998; 74 Suppl 2():75-85. PubMed ID: 9704427 [TBL] [Abstract][Full Text] [Related]
2. In vivo effects of Mpl ligand administration and emerging clinical applications for the Mpl ligands. Kuter DJ Curr Opin Hematol; 1997 May; 4(3):163-70. PubMed ID: 9209831 [TBL] [Abstract][Full Text] [Related]
3. [Therapeutic potential of thrombopoietin]. Geissler K Wien Klin Wochenschr; 2000 Oct; 112(19):829-34. PubMed ID: 11098533 [TBL] [Abstract][Full Text] [Related]
5. The use of PEG-rhuMGDF in platelet apheresis. Kuter DJ Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195 [TBL] [Abstract][Full Text] [Related]
6. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Schuster MW; Beveridge R; Frei-Lahr D; Abboud CN; Cruickshank S; Macri M; Menchaca D; Holden J; Waller EK Exp Hematol; 2002 Sep; 30(9):1044-50. PubMed ID: 12225796 [TBL] [Abstract][Full Text] [Related]
7. Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor. Harker LA; Marzec UM; Kelly AB; Cheung E; Tomer A; Nichol JL; Hanson SR; Stead RB Blood; 1997 Jan; 89(1):155-65. PubMed ID: 8978288 [TBL] [Abstract][Full Text] [Related]
8. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates. Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799 [TBL] [Abstract][Full Text] [Related]
9. What is the potential for thrombopoietic agents in acute leukemia? Kuter DJ Best Pract Res Clin Haematol; 2011 Dec; 24(4):553-8. PubMed ID: 22127320 [TBL] [Abstract][Full Text] [Related]
10. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Kuter DJ Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568 [TBL] [Abstract][Full Text] [Related]
11. The impact of thrombopoietin and related Mpl-ligands on transfusion medicine. Farese AM; Schiffer CA; MacVittie TJ Transfus Med Rev; 1997 Oct; 11(4):243-55. PubMed ID: 9345706 [No Abstract] [Full Text] [Related]
12. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Hussein S; Alt C; Menchaca D; Tomita D; Marty J; Fox RM; Begley CG Lancet; 1996 Nov; 348(9037):1279-81. PubMed ID: 8909381 [TBL] [Abstract][Full Text] [Related]
14. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Scheding S; Bergmann M; Shimosaka A; Wolff P; Driessen C; Rathke G; Jaschonek K; Brugger W; Kanz L Transfusion; 2002 Mar; 42(3):321-7. PubMed ID: 11961237 [TBL] [Abstract][Full Text] [Related]
15. Development of thrombopoietin receptor agonists for clinical use. Ikeda Y; Miyakawa Y J Thromb Haemost; 2009 Jul; 7 Suppl 1():239-44. PubMed ID: 19630808 [TBL] [Abstract][Full Text] [Related]
16. Embryonic stem cell differentiation to hematopoietic cells: A model to study the function of various regions of the intracytoplasmic domain of cytokine receptors in vitro. Filippi MD; Porteu F; Le Pesteur F; Rameau P; Nogueira MM; Debili N; Vainchenker W; de Sauvage FJ; Kupperschmitt AD; Sainteny F Exp Hematol; 2000 Dec; 28(12):1363-72. PubMed ID: 11146158 [TBL] [Abstract][Full Text] [Related]
18. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Basser RL; Rasko JE; Clarke K; Cebon J; Green MD; Grigg AP; Zalcberg J; Cohen B; O'Byrne J; Menchaca DM; Fox RM; Begley CG Blood; 1997 May; 89(9):3118-28. PubMed ID: 9129014 [TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Li J; Yang C; Xia Y; Bertino A; Glaspy J; Roberts M; Kuter DJ Blood; 2001 Dec; 98(12):3241-8. PubMed ID: 11719360 [TBL] [Abstract][Full Text] [Related]
20. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Vadhan-Raj S Semin Hematol; 2000 Apr; 37(2 Suppl 4):28-34. PubMed ID: 10831286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]